Bertani Lorenzo, Barberio Brigida, Tricò Domenico, Zanzi Federico, Maniero Daria, Ceccarelli Linda, Marsilio Ilaria, Coppini Francesca, Lorenzon Greta, Mumolo Maria Gloria, Zingone Fabiana, Costa Francesco, Savarino Edoardo Vincenzo
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, Italy.
Department of Surgery, Tuscany North-West ASL, Massa Apuane Hospital, 54100 Massa, Italy.
J Clin Med. 2021 Jul 24;10(15):3270. doi: 10.3390/jcm10153270.
During the coronavirus disease 2019 (COVID-19) pandemic, immunomodulatory therapies and hospital admission were suspected to increase the risk of infection. Nevertheless, patients with inflammatory bowel diseases (IBD) treated with intravenous (i.v.) biologics had to move to hospitals for drug infusion. We investigated the impact of hospitalisation in patients with IBD. We conducted a survey including consecutive IBD patients initially in clinical and biochemical remission treated with biologics at the end of the first lockdown period. Patients underwent the normally scheduled clinical visits, performed at hospital for i.v.-treated patients or at home for patients treated with s.c. drugs. We administered to all patients the Hospital Anxiety and Depression Scale (HADS) questionnaire and other 12 questions, specifically related to COVID-19 and its implications. A total of 189 IBD patients were recruited, 112 (59.3%) treated with i.v. drugs and 77 (40.7%) with s.c. ones. No relapses were recorded in either group (hospitalized vs. non-hospitalized, = ns), as well as which, COVID-19 infections were not demonstrated in patients in contact with people with suspected symptoms or directly experiencing them. The total HADS score obtained by the sum of all items was also almost identical between groups (37.1 ± 2.8 vs. 37.2 ± 2.8; = 0.98). In patients treated with i.v. drugs receiving a televisit ( = 17), the rate of satisfaction with telemedicine (58.8%) was significantly lower compared with those treated with s.c. drugs (94.8%; < 0.0005). Our results suggest that hospitalisation during the COVID-19 outbreak does not increase the risk of COVID-19 infection as well as the risk of IBD relapse; moreover, the similar levels of anxiety in both groups could confirm that there is no need to convert patients from i.v. to s.c. therapy.
在2019年冠状病毒病（COVID-19）大流行期间，免疫调节疗法和住院治疗被怀疑会增加感染风险。然而，接受静脉注射生物制剂治疗的炎症性肠病（IBD）患者不得不前往医院进行药物输注。我们调查了住院对IBD患者的影响。我们进行了一项调查，纳入了在第一次封锁期结束时接受生物制剂治疗且最初处于临床和生化缓解期的连续IBD患者。患者接受了正常安排的临床访视，静脉注射治疗的患者在医院进行，皮下注射药物治疗的患者在家中进行。我们向所有患者发放了医院焦虑抑郁量表（HADS）问卷以及另外12个与COVID-19及其影响相关的问题。总共招募了189例IBD患者，其中112例（59.3%）接受静脉注射药物治疗，77例（40.7%）接受皮下注射药物治疗。两组均未记录到复发情况（住院组与非住院组，P = 无显著性差异），与疑似症状患者接触或直接出现症状的患者中也未发现COVID-19感染。两组所有项目得分总和得出 的总HADS评分也几乎相同（37.1±2.8 vs. 37.2±2.8；P = 0.98）。在接受远程问诊的静脉注射药物治疗患者（n = 17）中 在接受远程问诊的静脉注射药物治疗患者（n = 17）中，与皮下注射药物治疗的患者相比，对远程医疗的满意度（58.8%）显著较低（94.8%；P < 0.0005）。我们的结果表明，COVID-19疫情期间住院治疗不会增加COVID-19感染风险以及IBD复发风险；此外，两组相似的焦虑水平可以证实无需将患者从静脉注射治疗转换为皮下注射治疗。
